Last reviewed · How we verify
Formulation B GS-248
At a glance
| Generic name | Formulation B GS-248 |
|---|---|
| Sponsor | Gesynta Pharma AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formulation B GS-248 CI brief — competitive landscape report
- Formulation B GS-248 updates RSS · CI watch RSS
- Gesynta Pharma AB portfolio CI